• Symbol Lookup
ACCESSWIRE ACCESSWIRE.mobi BAYSTREET.mobi

 
     WELCOME: Guest    LOGIN BECOME A MEMBER

FOLLOW US

     

Repros Therapeutics (RPRX) stock climbs on clinical results

Wednesday,30 January,2013

Repros Therapeutics Inc (NASDAQ: RPRX) stock gained 3.4% to $12.64 after the company this week announced that it now plans to provide clinical results from the first pivotal study, ZA-301, of Androxal, in the treatment of secondary hypogonadism in Q3 2013 instead of Q2 2013. Share volume was 97,700, compared to an all-day average of 110,300




 follow us:

       



 
                                          

copyright 1998 - 2014 BayStreet.ca Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes.
Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Data is provided by QuoteMedia.com